Close

HEB Financial Facts

Total costs and expenses: 2.83M
Research and development: 900K
See Full Income Statement

Accumulated deficit: -296.47M
Additional paid-in capital: 313.62M
See Full Balance Sheet

Hemispherx Biopharma, Inc. (HEB) Earnings

  |   Expand Research on HEB
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate N/A Revenue Growth Rate N/A
Average % Move 1-Wk after EPS N/A Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/14/16 Q316 -$0.30N/A N/A N/AN/A N/A Details
8/15/16 Q216 -$0.01N/A N/A N/AN/A N/A Details
5/16/16 Q116 -$0.01N/A N/A N/A$40.99M N/A Details
3/29/16 Q415 N/AN/A N/A N/AN/A N/A N/A N/A
8/13/15 Q215 -$0.04N/A N/A N/AN/A N/A Details
5/13/15 Q115 -$0.02N/A N/A N/AN/A N/A Details
11/8/13 Q313 -$0.03N/A N/A N/AN/A N/A Details
11/5/12 Q312 -$0.04N/A N/A N/AN/A N/A Details